|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | ||||
| Depreciation and amortization | ||||
| Amortization of deferred costs | ||||
| Non-cash operating lease expense | ||||
| Loss on retirement of property, plant and equipment | ||||
| Loss on write-off of deferred stock issuance costs | ||||
| Impairment and other | ||||
| Other non-cash items | ||||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable, net | ||||
| Inventories | ||||
| Deferred costs | ||||
| Prepaid expenses and other current assets | ||||
| Other assets | ||||
| Accounts payable | ||||
| Accrued and other current liabilities | ||||
| Deferred revenue | ||||
| Deferred grant | ||||
| Operating lease liabilities | ||||
| Net cash used in operating activities | ||||
| Cash flows from investing activities: | ||||
| Purchase of property, plant and equipment | ||||
| Net cash used in investing activities | ||||
| Cash flows from financing activities: | ||||
| Proceeds from issuance of common stock in connection with the At Market Issuance Sales Agreement, net | ||||
| At Market Issuance Sales Agreement | ||||
| Common Stock Purchase Agreement | ||||
| Proceeds from issuance of common stock upon exercise of stock warrants | ||||
| Capital contributions from Amprius Holdings | ||||
| Payment of equity financing costs | ||||
| At Market Issuance Sales Agreement | ||||
| Total payment of equity financing costs | ||||
| Proceeds from issuance of common stock in connection with Business Combination and PIPE investment | ||||
| Payment of transaction and issuance costs in connection with Business Combination and PIPE investment | ||||
| Proceeds from exercise of stock options | ||||
| Net cash provided by financing activities | ||||
| Net increase (decrease) in cash, cash equivalents and restricted cash equivalents | ||||
| Net increase in cash, cash equivalents and restricted cash equivalents | ||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | ||||
| Cash, cash equivalents and restricted cash equivalents, beginning of year | ||||
| Cash, cash equivalents and restricted cash equivalents, end of year | ||||
| Supplemental non-cash investing and financing activities: | ||||
| Unpaid purchases of property, plant and equipment | ||||
| Unpaid financing costs in connection with a stock purchase agreement | ||||
| Increase in fair value of modified stock warrants | ||||
| Cancellation and retirement of common stock | ||||
| Reconciliation of cash, cash equivalents and restricted cash equivalents shown on the consolidated balance sheets: | ||||
| Cash and cash equivalents | ||||
| Restricted cash included in other assets | ||||
| Restricted cash equivalents included in prepaid expenses and other current assets | ||||
| Restricted cash equivalents included in other assets | ||||
Loading...